12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MGCD290: Phase I data

In a double-blind, placebo-controlled, Canadian Phase I trial (Study 290-004) in 16 healthy volunteers, 270 and 540 mg/day oral MGCD290 plus 400 mg...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >